Nikhil Wagle, MD, Dana-Farber Cancer Institute, discusses the genomic sequencing of ER-positive metastatic breast cancer that has become resistant to therapies and the implications for the choice of next therapy, clinical trial eligibility, and novel drug targets (Abstract S1-01).
Peter Bach, MD, of Memorial Sloan Kettering Cancer Center, summarizes his plenary lecture on drug costs and their effect on the affordability of cancer care worldwide (Plenary Lecture 3).
Stephen R.D. Johnston, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss the role of endocrine therapy and optimal sequencing, recent progress in first-line treatment, and resistance pathways and second-line treatment (Plenary Lecture 1).
Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.
Sabine Linn, MD, PhD, and Sonja Vliek, MD, both of the Netherlands Cancer Institute, discuss study findings on adjuvant ibandronate in postmenopausal women with early breast cancer (Abstract S6-02).
Rowan T. Chlebowski, MD, PhD, of the David Geffen School of Medicine at UCLA, discusses findings from the Women’s Health Initiative Dietary Modification study on low-fat diet and breast cancer overall survival (Abstract S5-04).
